Login to Your Account

Tracon Licenses D93 Antibody From Micromet

By Trista Morrison

Monday, March 19, 2007
In a deal worth up to $100 million, Micromet Inc. licensed the preclinical anti-angiogenesis monoclonal antibody D93 to privately held Tracon Pharmaceuticals Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription